Immunosuppression and Treatment of Rejection

  • M. Roy First


The introduction in the 1980s of cyclosporine and monoclonal antibodies represented a major therapeutic advance in solid organ transplantation. The United Network for Organ Sharing (UNOS) has recently released the 1- and 2-year graft and patient survival rates for solid organ transplants (1). These survival rates are illustrated in Table 1. Currently, there are a number of promising new immunosuppressive agents on the horizon, and it appears likely that further advances will be made in our ability to control the immune response (2,3). A dynamic interaction exists between basic immunology and clinical transplantation. Advances in immunobiology have resulted in a better understanding of the immunological events involved in the recognition of and response to transplant antigens and have led to a better understanding of the action of various immunosuppressive agents. This chapter reviews the mechanisms involved in the immune response, how currently used immunosuppressive agents act, the possible role for future immunosuppressive drugs, the current approach to clinical immunosuppressive therapy, and the diagnosis and treatment of acute rejection.


Acute Rejection Allograft Rejection Renal Allograft Transplant Proc Rejection Episode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Annual Report of the U. S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplant Network, Executive Summary. U.S. Department of Health and Human Services, Library of Congress Catalog Card Number 93–060966, p 22, 1993.Google Scholar
  2. 2.
    First MR: Transplantation in the nineties. Transplantation 53: 1–11, 1992.PubMedCrossRefGoogle Scholar
  3. 3.
    First MR: New immunosuppressive drugs. Am J Kidney Dis 19: 3–9, 1992.PubMedGoogle Scholar
  4. 4.
    Thorsby E: Structure and function of HLA-molecules. Transplant Proc 19: 29–35, 1987.PubMedGoogle Scholar
  5. 5.
    Strom TB, Tilney NL: Immunobiology and immunopharmacology of graft rejection. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney. Little, Brown, Boston, pp 2879–2910, 1993.Google Scholar
  6. 6.
    Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J: The role of the antigen receptor complex in T-cell activation. Annu Rev Immunol 4: 593–619, 1986.PubMedCrossRefGoogle Scholar
  7. 7.
    Williams JM, DeLoria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM, Strom TB: The events of primary T cell activation can be staged by use of sepharose bound anti-T3 (64.1) monoclonal antibody and interleukin-1. J Immunol 135: 2249–2255, 1985.PubMedGoogle Scholar
  8. 8.
    Moore RN, Oppenheim JJ, Farrar JJ, Carter CS, Waheed A, Shadduck RK: Production of LAF (IL-1) by macrophages activated by colony stimulating factors. J Immunol 125: 1302 1305, 1980.Google Scholar
  9. 9.
    Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional relationship of the interleukins. J Exp Med 151: 1551–1556, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Farrar WL, Johnson HM, Farrar JJ: Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin-2. J Immunol 126: 1120–1125, 1981.PubMedGoogle Scholar
  11. 11.
    Inaba K, Granelli-Piperno G, Steinman RM: Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin-2-dependent mechanism. J Exp Med 158: 2040–2057, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Cantrell DA, Smith KA: The interleukin-2 T cell system: a new cell growth model. Science 224: 1312–1316, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Moscovitch-Lopatin M, Petrillo RJ, Pankewycz O, Hadro E, Bleackley CR, Strom TB, Wieder KJ: Interleukin-2 counteracts the inhibition of cytotoxic T lymphocytes by cholera toxin in vitro and in vivo. Eur J Immunol 21: 1439–1444, 1991.PubMedCrossRefGoogle Scholar
  14. 14.
    Kelley VE, Fiers W, Strom TB: Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemia cell lines. J Immunol 132: 240–245, 1984.PubMedGoogle Scholar
  15. 15.
    Pober JS, Gimbrone MA, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA: Ia expression by vascular endothelium is inducible by activated T cells and by human gamma-interferon. J Exp Med 157: 1339–1353, 1983.PubMedCrossRefGoogle Scholar
  16. 16.
    Fabre JW, Milton AD, Spencer S, Settaf A, Houssin D: Regulation of alloantigen expression in different tissues. Transplant Proc 19: 45–49, 1987.PubMedGoogle Scholar
  17. 17.
    Lu CY, Sicher SC, Vazquez MA: Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies. J Am Soc Nephrol 4: 1239–1256, 1993.PubMedGoogle Scholar
  18. 18.
    Hall BM: Cellular infiltrates in allografts. Transplant Proc 19: 50–56, 1987.PubMedGoogle Scholar
  19. 19.
    Han J, Thompson B, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391–394, 1990.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee SW, Tsou AP, Chan H, Thomas J, Petrie K, Euglei EM, Allison AC: Glucorticoids selectively inhibit the transcription of the interleukin-1 beta gene and decrease the stability of interleukin-1 beta gene mRNA. Proc Natl Acad Sci USA 85: 1204–1208, 1988.PubMedCrossRefGoogle Scholar
  21. 21.
    Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Golino A: Glucorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175: 637–646, 1992.PubMedCrossRefGoogle Scholar
  22. 22.
    Northrop JP, Crabtree GR, Mattila PS: Negative regulation of interleukin-2 transcription by the glucocorticoid receptor. J Exp Med 175: 1235–1245, 1992.PubMedCrossRefGoogle Scholar
  23. 23.
    Zimmer T, Jones PP: Combined effects of tumor necrosis factor-alpha, prostaglandin E2, and corticosterone on induced la expression on murine macrophages. J Immunol 145: 1167–1175, 1991.Google Scholar
  24. 24.
    Politis AD, Sivo J, Driggers PH, Ozato K, Vogel SN: Modulation of interferon consensus sequence binding protein mRNA in murine peritoneal macrophages: induction by INF-y and down-regulation by INF-a, dexamethasone, and protein kinase inhibitors. J Immunol 148: 801–807, 1992.PubMedGoogle Scholar
  25. 25.
    Knudsen PJ, Dinarello CA, Strom TB: Glucorticoids inhibit transcription and post-transcription of interleukin-1. J Immunol 139: 4129–4134, 1987.PubMedGoogle Scholar
  26. 26.
    Zanker B, Walz G, Wieder KJ, Strom TB: Evidence that glucocorticoids block expression of the human interleukin6 gene by accessory cells. Transplantation 49: 183–185, 1990.PubMedCrossRefGoogle Scholar
  27. 27.
    Elion GB: Biochemistry and pharmacology of purine analogues. Fed Proc 26: 898–904, 1967.PubMedGoogle Scholar
  28. 28.
    Rossi SJ, Schroeder TJ, Hariharan S, First MR: Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety 9: 104–131, 1993.PubMedCrossRefGoogle Scholar
  29. 29.
    First MR, Alexander JW, Wadhwa N, Penn I, Munda R, Fidler JP, Weisskittel P: The use of low dose cyclosporine, azathioprine and prednisone in renal transplantation. Transplant Proc 18 (Suppl 1): 132–135, 1986.PubMedGoogle Scholar
  30. 30.
    Levine LA, Richie JP: Urological complications of cyclophosphamide. J Uro1141:1063–1069, 1989.Google Scholar
  31. 31.
    First MR: Renal allograft survival after 1 and 10 years: Comparison between pre-cyclosporin and cyclosporin data. Nephrol Dial Transplant 9: 90–97, 1993.Google Scholar
  32. 32.
    Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283–287, 1991.PubMedCrossRefGoogle Scholar
  33. 33.
    Walsh CT, Zydowsky LD, McKeon FD: Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 267: 13115–13118, 1992.PubMedGoogle Scholar
  34. 34.
    Feutren G, Mihatsch MJ: Risk factors for cyclosporineinduced nephropathy in patients with autoimmune disease. N Engl J Med 326: 1654–1660, 1992.PubMedCrossRefGoogle Scholar
  35. 35.
    Myers B: Cyclosporine nephrotoxicity. Kidney Int 30: 964974, 1986.Google Scholar
  36. 36.
    Curtis J, Luke R, Jones P, Diethelm A: Hypertension in cyclosporine renal transplant recipients is sodium dependent. Am J Med 85: 134–138, 1988.PubMedCrossRefGoogle Scholar
  37. 37.
    First MR, Neylan JF, Rocher LL, Tejani A: Hypertension after renal transplantation. J Am Soc Nephrol 4 (Suppl 1): S30 - S36, 1994.PubMedGoogle Scholar
  38. 38.
    Kahan BD: Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis. Am J Kidney Dis 8: 323–331, 1986.PubMedGoogle Scholar
  39. 39.
    Kahan BD: Cyclosporine. N Engl J Med 321: 1725–1738, 1989.PubMedCrossRefGoogle Scholar
  40. 40.
    Cosimi AB, Delmonico FL: Antilymphocyte antibody therapy. In: JF Burdick, LC Rascusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 541–565, 1992.Google Scholar
  41. 41.
    Filo RS, Smith EJ, Leapman SB: Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 30: 444–449, 1980.CrossRefGoogle Scholar
  42. 42.
    Streem SB, Novick AC, Braun WE, Steinmuller D, Greenstreet R: Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. Transplantation 35: 420–424, 1983.PubMedCrossRefGoogle Scholar
  43. 43.
    Diflo T, Monaco AP: Clinical immunosuppressive drug therapy. In: AW Thomson, GRD Catto, eds, Immunology of Renal Transplantation. Edward Arnold, London, pp 255–263, 1993.Google Scholar
  44. 44.
    O’Connelll PJ, Corpier CL, Steele A, Strom T: Monoclonal antibody therapy. In: AW Thomson, GRD Catto, eds, Immunology of Renal Transplantation. Edward Arnold, London, pp 281–302, 1993.Google Scholar
  45. 45.
    Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russel PS: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305: 308–314, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Cosimi AB: OKT3: first-dose safety and success. Nephron 46: 12–18, 1987.PubMedCrossRefGoogle Scholar
  47. 47.
    Schroeder TJ, First MR: Monoclonal antibodies in organ transplantation. Am J Kidney Dis 23: 138–147, 1994.PubMedGoogle Scholar
  48. 48.
    Ortho Multicenter Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337–342, 1985.CrossRefGoogle Scholar
  49. 49.
    Thistlethwaite JR, Gaber AO, Haag BW, Arouson AJ, Broelsch CE, Stuart JK, Stuart FP: OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation 43: 176–184, 1987.PubMedCrossRefGoogle Scholar
  50. 50.
    Norman DJ, Shield CF: OKT3: first-line therapy or last option? Transplant Proc 18: 949–953, 1986.Google Scholar
  51. 51.
    Norman DJ, Barry JM, Bennett WM, Leone M, Henell K, Funnell B, Hubert B: The use of OKT3 in cadaveric renal transplantation that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 11: 90–93, 1988.PubMedGoogle Scholar
  52. 52.
    Schroeder TJ, Weiss MA, Smith RD, Stephens GW, Carey M, First MR: The efficacy of OKT3 in vascular rejection. 51: 312–315, 1991.Google Scholar
  53. 53.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I: Prophylactic use of OKT3 in immunological high risk renal transplant recipients. Am J Kidney Dis 14 (Suppl 2): 14–18, 1989.PubMedGoogle Scholar
  54. 54.
    Cardella CJ, Blake P, Cattran D, Cole E: Prophylactic OKT3 in renal retransplantation. Transplant Proc 21: 3373–3374, 1989.PubMedGoogle Scholar
  55. 55.
    Benvensky AJ, Cohen D, Stegall MD, Hardy MA: Improved results using OKT3 as induction immunosuppression in cadaver kidney recipients. Transplantation 49: 321–327, 1990.CrossRefGoogle Scholar
  56. 56.
    Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF, Monaco A, Dehlinger J, Wu SC, Vanhorn A, Haverty TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55: 44–50, 1993.PubMedCrossRefGoogle Scholar
  57. 57.
    Abram000wicz D, Schandene L, Goldman M, Crusiaux A, Vereestraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor-alpha, interleukin-2 and interferon-gamma in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Trsansplantation 47: 606–608, 1989.CrossRefGoogle Scholar
  58. 58.
    Chatenoud L, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320: 1420–1421, 1989.PubMedCrossRefGoogle Scholar
  59. 59.
    Suthanthiran M, Fotino M, Giggio RR, Cheigh JS, Stenzel KH: OKT3 associated adverse reactions: mechanistic basis and therapeutic options. Am J Kidney Dis 14 (Suppl 2): 3944, 1989.Google Scholar
  60. 60.
    First MR, Schroeder TJ, Hariharan S: The OKT3-induced cytokine release syndrome: renal effects (cytokine nephropathy). Transplant Proc 25 (Suppl 1): 25–26, 1993.PubMedGoogle Scholar
  61. 61.
    Chatenoud L, Legendre C, Ferran C, Bach J, Kreis H: Corticosteroid inhibition of the OKT3-induced cytokine-release syndrome: dosage and kinetic prerequisites. Transplantation 51: 334–338, 1991.PubMedCrossRefGoogle Scholar
  62. 62.
    First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P: The effect of indomethacin on the febrile response following OKT3 therapy. Transplantation 53: 91–94, 1992.PubMedCrossRefGoogle Scholar
  63. 63.
    Alegre M, Gastadello K, Abramoowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vandenabeele P, Moser M, Leo O, Goldman M. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52: 674–679, 1991.PubMedCrossRefGoogle Scholar
  64. 64.
    Chatenoud L: OKT3-induced cytokine-release syndrome: preventive effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 25 (Suppl 1): 47–51, 1993.PubMedGoogle Scholar
  65. 65.
    Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB: Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 aristing despite intense immunosuppression. Transplantation 41: 572–578, 1986.PubMedCrossRefGoogle Scholar
  66. 66.
    Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Bach JF: Restriction of the human in vivo response against the mouse monoclonal antibody OKT3. J Immunol 137: 830–838, 1986.PubMedGoogle Scholar
  67. 67.
    Nelson PW, Jaffers GJ, Fuller TC, Cosimi AB, Colvin RB: Reduction of immune response to OKT3 monoclonal antibody. Transplant Proc 17: 644–645, 1985.Google Scholar
  68. 68.
    Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Balistreri WF, Alexander JW: Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48–51, 1990.PubMedCrossRefGoogle Scholar
  69. 69.
    Hricik DE, Mayes JT, Schulak JA: Inhibition of anti-OKT3 antibody generation by cyclosporine: results of a prospective randomized trial. Transplantation 50: 237–240, 1990.PubMedCrossRefGoogle Scholar
  70. 70.
    First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP, Ryckman FC, Brunson ME: Successful retreatment of allograft rejection with OKT3. Transplantation 47: 88–91, 1989.PubMedCrossRefGoogle Scholar
  71. 71.
    Kahan BD: Synergism: how assessed and how achieved. Clin Transplantation 5: 534–539, 1991.Google Scholar
  72. 72.
    Groth CG, Ohlman S, Gannedahl G, Ericzon BG: New immunosuppressive drugs in transplantation. Transplant Proc 25: 2681–2683, 1993.PubMedGoogle Scholar
  73. 73.
    Morris RE: Primer on new small molecule immunosuppressants. Transplant Soc Bull 1: 15–21, 1993.Google Scholar
  74. 74.
    Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K, Kashiwagi N: Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplantaion 35: 144–145, 1983.CrossRefGoogle Scholar
  75. 75.
    Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS: Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87: 940–948, 1991.PubMedCrossRefGoogle Scholar
  76. 76.
    Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprine, 6mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41: 671–676, 1992.PubMedGoogle Scholar
  77. 77.
    Tajima A, Hata M, Ohta N, Ohtawara Y, Suzuki K, Aso Y: Bredinin treatment in clinical kidney allografting. Transplantation 38: 116–118, 1984.PubMedCrossRefGoogle Scholar
  78. 78.
    Gregory CR, Gourley IM, Cain GR, Broaddus TW, Cowgill LD, Willits NH, Patz JD, Ishizaki G: Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. Transplantation 45: 856–859, 1988.PubMedCrossRefGoogle Scholar
  79. 79.
    Marumo F, Okubo M, Yokota K, Uchida H, Kumano K, Endo T, Watanabe K, Kashiwagi N: A clinical study of renal transplant patients receiving triple-drug therapycyclosporine A, mizoribine, and prednisolone. Transplant Proc 20 (Suppl 1): 406–409, 1988.PubMedGoogle Scholar
  80. 80.
    Hayashi R, Suzuki S, Shimatani K, Watanabe H, Kenmochi T, Fukuoka T, Niiya S, Amemiya H: Synergistic effect of cyclosporine and mizoribine on graft survival in canine organ transplantation. Transplant Proc 22: 1676–1678, 1990.PubMedGoogle Scholar
  81. 81.
    Mita K, Akiyama N, Nagao T, Sugimoto H, Inoue S, Osakabe T, Nakayama Y, Yokota K: Advantages of mizoribine over azathioprine combination therapy with cyclosporine for renal transplantation. Transplant Proc 22: 1679–1681, 1990.PubMedGoogle Scholar
  82. 82.
    Kokado Y, Ishibahi M, Jiang H, Takahara S, Sonoda T: Low-dose ciclosporin, mizoribine and prednisolone in renal transplantation: a new triple-drug therapy. Clin Transplant 4: 191–197, 1990.Google Scholar
  83. 83.
    Lee HA, Slapak M, Venkatraman G, Mason J, Digard N, Wise M: Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation. Transplant Proc 25: 2699–2700, 1993.PubMedGoogle Scholar
  84. 84.
    Gregory CR, Gourley IM, Cain GR, Patz JD, Imondi KA, Martin JA: Mizoribine serum levels associated with enterotoxicity in the dog. Transplantation 51: 877–881, 1991.PubMedCrossRefGoogle Scholar
  85. 85.
    Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, Sonoda T, Takahashi M: Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transplant Proc 22: 1682–1685, 1990.PubMedGoogle Scholar
  86. 86.
    Morris RE, Hoyt EG, Murphy MP: Mycophenolic acid morpholinoedthylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22: 1659–1662, 1990.PubMedGoogle Scholar
  87. 87.
    Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of mycophenolic acid and an es-ter pro-drug, RS-61443. Transplant Proc 23 (Suppl 2): 10–14, 1991.PubMedGoogle Scholar
  88. 88.
    Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23 (Suppl 2): 15–18, 1991.PubMedGoogle Scholar
  89. 89.
    Platz KP, Eckhoff DE, Hullet DA, Sollinger HW: RS-61443 studies: review and proposal. Transplant Proc 23 (Suppl 2): 33–35, 1991.PubMedGoogle Scholar
  90. 90.
    Sollinger HW, Eugui EM, Allison AC: RS-61443: mechanism of action, experimental and early clinical results. CLin Transplant 5: 523–526, 1991.Google Scholar
  91. 91.
    Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33: 161–173, 1991.PubMedCrossRefGoogle Scholar
  92. 92.
    Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 33: 175–183, 1991.PubMedCrossRefGoogle Scholar
  93. 93.
    Hao L, Lafferty KJ, Allison AC, Eugui EM: RS-61443 allows islet allografting and specific tolerance in mice. Transplant Proc 22: 876–879, 1990.PubMedGoogle Scholar
  94. 94.
    Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ, Chu N, Tam YL, Kaloostian M, Allison AC, Eugui EM: Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23 (Suppl 2): 19–25, 1991.PubMedGoogle Scholar
  95. 95.
    Platz KP, Sollinger HW, Hullett DA: RS-61443—A new, potent immunosuppressive agent. Transplantation 51: 27–31, 1991.PubMedCrossRefGoogle Scholar
  96. 96.
    Knechtle SJ, Wang J, Beesku M, Burlingham WJ, Sollinger HW, Belzer FO: Effect of RS-61443 in preventing rejection in sensitized recipients. Surg Forum 41: 380–381, 1990.Google Scholar
  97. 97.
    Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443—A phase I clinical trial and pilot rescue study. Transplantation 53: 428–432, 1992.PubMedCrossRefGoogle Scholar
  98. 98.
    Deierhoi MH, Solinger HW, Diethelm AG, Belzer FO, Kauffman RS: One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 25: 693–694, 1993.PubMedGoogle Scholar
  99. 99.
    Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG: Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 217: 476–484, 1993.PubMedCrossRefGoogle Scholar
  100. 100.
    Salaman JR, Griffin PJA, Johnson RWG, Kohlhaw K, Land W, Moore R, Pichlmayr R, Sells R: Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc 25: 695–696, 1993.PubMedGoogle Scholar
  101. 101.
    Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443: rescue therapy in refractory kidney transplant rejection. Transplant Proc 25: 698–699, 1993.PubMedGoogle Scholar
  102. 102.
    Klintmalm GB, Ascher NL, Busuttil RW, Deierhoi M, Gonwa TA, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, Roberts J: Rs-61443 for treatment—resistant human liver rejection. Transplant Proc 25: 697, 1993.PubMedGoogle Scholar
  103. 103.
    Simon P, Townsend RM, Harris RR, Jones EA, Jaffe BD: Brequinar sodium: inhibition of dihydrorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro. Transplant Proc 25 (Suppl 2): 77–80, 1993.PubMedGoogle Scholar
  104. 104.
    Makowka L, Cramer DV: Brequinar sodium: a new immunosuppressive drug for transplantation. Transplant Sci 2: 50–54, 1992.Google Scholar
  105. 105.
    Cramer DV, Chapman FA, Jaffee BD, Jones EA, Knoop M, Hreha-Eiras G, Makowka L: The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 53: 303–308, 1992.PubMedCrossRefGoogle Scholar
  106. 106.
    Cramer DV, Chapman FA, Makowka L: Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium. Transplant Proc 25 (Suppl 2): 23–28, 1993.PubMedGoogle Scholar
  107. 107.
    Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L: Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection. Transplant Proc 25 (Suppl 2): 57–58, 1993.PubMedGoogle Scholar
  108. 108.
    Makowka L, Tixier D, Chaux A, Hill D, O’Neill P, EirasHreha G, Wu GD, Cunneen S, Cajulis E, Zajac I, Jaffee BD, Chapman FA, Cramer DV: Use of brequinar sodium for preventing cardiac allograft rejection in primates. Transplant Proc 25 (Suppl 2): 48–53, 1993.PubMedGoogle Scholar
  109. 109.
    Collins BH, Areford ML, Fabian MA, Jaffee BD, Bollinger RR: Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. Transplant Proc 25 (Suppl 2): 37–39, 1993.PubMedGoogle Scholar
  110. 110.
    Stepkowski SM, Kahan BD: Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar. Transplant Proc 25 (Suppl 2): 29–31, 1993.PubMedGoogle Scholar
  111. 111.
    Hullett DA, Sollinger HW: Mycopyhenolate mofetil and brequinar sodium: new immunosuppressive agents. Transplant Proc 25 (Suppl 2): 45–47, 1993.PubMedGoogle Scholar
  112. 112.
    Yasunaga C, Cramer DV, Cosenz CA, Tuso PJ, Chapman FA, Barnett M, Mu GD, Putnam BA, Makowka L: Effect of brequinar sodium on in vivo antibody production. Transplant Proc 25 (Suppl 2): 40–44, 1993.PubMedGoogle Scholar
  113. 113.
    Ptachinski RJ, Burckart GJ, Venkataramanan R: Cyclosporine concentration determinations for monitoring and pharmacokinetic studies. J Clin Pharmacol 26: 358–366, 1986.CrossRefGoogle Scholar
  114. 114.
    Lindholm A, Welsh M, Rutzky L, Kahan BD: The adverse impact of high cyclosporine clearance rates on the incidence of acute rejection and graft loss. Transplantation 55: 985–993, 1993.PubMedCrossRefGoogle Scholar
  115. 115.
    Meyer MM, Munar M, Udeaja J, Bennett W: Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 4: 1306–1315, 1993.PubMedGoogle Scholar
  116. 116.
    Ritschel WA, Adolph S, Ritschel GB, Schroeder T: Improvement of peroral absorption of cyclosporine A by microemulsions. Methods Find Exp Clin Pharmacol 12: 127134, 1990.Google Scholar
  117. 117.
    Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 13: 613617, 1993.Google Scholar
  118. 118.
    Mueller EA, Kovarik JM, van Brel JB, Lison AE, Kutz K: Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients—a concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178–1182, 1994.PubMedCrossRefGoogle Scholar
  119. 119.
    Vonderscher J, Meinzer A: Rational for the development of Sandimmune Neoral. Transplant Proc 26: 2925–2927, 1994.PubMedGoogle Scholar
  120. 120.
    Holt DW, Mueller EA, Kovarik JM, van Bull JB, Kutz K: The pharmacokinetics of Sandimmune Neoral: a new oral formulation of cyclosporine. Transplant Proc 26: 2935–2939, 1994.PubMedGoogle Scholar
  121. 121.
    Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Chang C, Choc M, Wong R: The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 26: 2940–2943, 1994.PubMedGoogle Scholar
  122. 122.
    Superina RA, Strong DK, Acal LA, DeLuca E: Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Transplant Proc 26: 2979–2980, 1994.PubMedGoogle Scholar
  123. 123.
    Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV: Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc 26: 2977–2978, 1994.PubMedGoogle Scholar
  124. 124.
    Storck M, Mickley V, Grab C, Steinbach G, Abendroth D: Cyclosporine levels in diabetic (Type I) patients undergoing kidney and pancreas transplantation: role of a new galenic formulation. Transplant Proc 26: 2996–2998, 1994.PubMedGoogle Scholar
  125. 125.
    Fiocchi R, Mamprin F, Gamba A, Glauber M, Catania S, Cattaneo G, Torre L, Bertocchi C, Ruhrmann R, Colombo D, Binetti G, Ferrazzi P: Pharmacokinetic profile of cyclosporin A in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 26: 2994–2995, 1994.PubMedGoogle Scholar
  126. 126.
    Neumayer HH, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmer J, Waiser J: Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after one month. Transplant Proc 26: 2944 2988, 1994.Google Scholar
  127. 127.
    Duncan JI, Thomson AW, Simpson JG, Davidson RJL, Whiting PH: A comparative toxicology study of cyclosporine and Nva-2 cyclosporine in Sprague–Dawley rats. Transplantation 42: 395–399, 1986.PubMedCrossRefGoogle Scholar
  128. 128.
    McKenna RM, Szturm K, Jeffrey JR, Rush DN: Inhibition of cytokine production by cyclosporine A and G. Transplantation 47: 343–348, 1989.PubMedCrossRefGoogle Scholar
  129. 129.
    Hiestand PC, Traber R, Borel JF: Pharmacological studies with norvaline 2–cyclosporine (SD2 OG 37–325) in comparison with cyclosporin (Sandimmun): a summary. Transplant Proc 26: 2999–3001, 1994.PubMedGoogle Scholar
  130. 130.
    Hagberg RC, Hoyt EG, Billingham ME, Sibley RK, Scarnes VA, Baldwin JC: Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive activity, toxicity, and pharmacokinetics in Lewis rats. J Heart Transplant 7: 359–369, 1988.PubMedGoogle Scholar
  131. 131.
    Masri MA, Naiem M, Pingle S, Daar AS: Cyclosporine A versus cyclosporine G: a comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice. Transplant Int 1: 13–18, 1988.CrossRefGoogle Scholar
  132. 132.
    Burdmann EA, Andoh TF, Rosen S, Lindsley J, Munar MY, Elzinga LW, Bennett WM: Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 45: 684–691, 1994.PubMedCrossRefGoogle Scholar
  133. 133.
    Huser B, Thiel G, Oberholzer M, Beveridge T, Bianchi L, Mihatsch MJ, Landmann J: The efficacy and tolerability of cyclosporine G in human kidney transplant recipients. Transplantation 54: 65–69, 1992.PubMedCrossRefGoogle Scholar
  134. 134.
    Henry ML, Tesi RJ, Elkhammas EA, Ferguson RM: A randomized, prospective, double-blinded study of cyclosporine vs. 0G37–325 in cadaveric renal transplantation—a preliminary report. Transplantation 55: 748–752, 1993.PubMedCrossRefGoogle Scholar
  135. 135.
    Hiestand PC, Graber M, Hurtenbach U, Herrmann P, Cammisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B, Borel JF: New cyclosporine derivative SD2IMM125: in vitro and in vivo pharmacologic effects and toxicologic evaluation. Transplant Proc 25: 691–692, 1993.PubMedGoogle Scholar
  136. 136.
    Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H: FK506, a novel immunosuppressant isolated from a streptomyces. Immunosuppressive effect of FK506 in vitro. J Antibiot 40: 1256–1260, 1987.PubMedCrossRefGoogle Scholar
  137. 137.
    Thompson AW: FK-506: profile of an important new immunosuppressant. Transplant Rev 4: 1–13, 1990.CrossRefGoogle Scholar
  138. 138.
    Johansson A, Moller E: Evidence that the immunosuppressive effects of FK-506 and cyclosporine are identical. Transplantation 50: 1001–1007, 1990.PubMedCrossRefGoogle Scholar
  139. 139.
    Wood RP, Katz SM, Kahan BD: New immunosuppressive agents. Transplant Sci 1: 34–46, 1991.Google Scholar
  140. 140.
    Peters DH, Fittow A, Plosker GL, Faulds D: Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 46: 746–794, 1993.PubMedCrossRefGoogle Scholar
  141. 141.
    Bierer BE, Schreiber SL, Burakoff SJ: Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. Transplantation 49: 1168–1170, 1990.PubMedCrossRefGoogle Scholar
  142. 142.
    Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL: Probing immunosuppressant action with a nonnatural ligand Science 250: 556–559, 1990.PubMedCrossRefGoogle Scholar
  143. 143.
    Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J: Atomic structure of FKBP-FK506, an immunophilinimmunosuppressant complex. Science 252: 839–842, 1991.PubMedCrossRefGoogle Scholar
  144. 144.
    Suzuki N, Sakane T, Tsunematsu T: Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Clin Exp Immunol 79: 240–245, 1990PubMedCrossRefGoogle Scholar
  145. 145.
    Lagodzinski Z, Gorski A, Stepien-Sonpniewska B, Wasik M: Effect of FK506 on B-cell responses. Transplant Proc 23: 94 2943, 1991.Google Scholar
  146. 146.
    Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T, Goto T, Hori S, Kenmochi T, Nakagoori T, Isono K: Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 19: 1284–1286, 1987.PubMedGoogle Scholar
  147. 147.
    Murase N, Kim D, Todo S, Cramer DV, Fung JJ, Starzl TE: Suppression of allograft rejection with FK506. Transplantation 50: 186–189, 1990.PubMedCrossRefGoogle Scholar
  148. 148.
    Hildebrandt A, Meiser B, Human P, Reichenspurner H, Rose A, Odell J, Reichart B: FK506: short-and long-term treatment after cardiac transplantation in nonhuman primates. Transplant Proc 23: 509–510, 1991.PubMedGoogle Scholar
  149. 149.
    Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S: Kidney transplantation under FK506. JAMA 264: 63–67, 1990.PubMedCrossRefGoogle Scholar
  150. 150.
    Japanese FK506 Study Group: Japanese study of FK506 in kidney transplantation: results of an early phase II study. Transplant Proc 23: 3071–3074, 1991.Google Scholar
  151. 151.
    Fung JJ, Shapiro R, Armitage J, Starzl TE: Influence of FK506 in clinical transplantation. In: AW Thomson, TE Starzl, eds, Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. Edward Arnold, London, pp 121128, 1994.Google Scholar
  152. 152.
    Jordan ML, Shapiro R, Vivas CA, Scantleburg VP, Darras FS, Carrieri G, McCauley J, Demetris AJ, Randhawa P, Jensen C, Hakala TR, Fung JJ, Starzl TE: FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25: 638–640, 1993.PubMedGoogle Scholar
  153. 153.
    Jordan ML, Shapiro R, Jensen CWP, Scantleburg V, Fung J, Tzakis A, McCauley J, Jain A, Demetris A.1, Randhawa P, Simmons RL, Hakala TR, Starzl TE: FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 23: 3078–3081, 1991.PubMedGoogle Scholar
  154. 154.
    Tzakis AG, Reyes J, Todo S, Nour B, Shapiro R, Jordan M, McCauley J, Armitage J, Fung JJ, Starzl TE: Two-year experience with FK506 in pediatric patients. Transplant Proc 25: 619–621, 1993.PubMedGoogle Scholar
  155. 155.
    European FK506 Multicenter Liver Group: Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423–428, 1994.CrossRefGoogle Scholar
  156. The U.S. Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110–1115, 1994.Google Scholar
  157. 157.
    Klintmalm G: A review of FK506: a new immunosuppressant agent for the prevention and rescue of graft rejection. Transplant Rev 8: 53–63, 1994.CrossRefGoogle Scholar
  158. 158.
    McCauley J: The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 2: 662–669, 1993.PubMedCrossRefGoogle Scholar
  159. 159.
    Demetris AJ, Banner B, Fung J, Shapiro R, Jordan M, Starzl TE: Histopathology of human renal allograft rejection under FK506: a comparison with cyclosporine. Transplant Proc 23: 944–946, 1991.PubMedGoogle Scholar
  160. 160.
    Japanese FK506 Study Group: Japanese study of FK506 on kidney transplantation: results of a late phase II study. Transplant Proc 25: 649–654, 1993.Google Scholar
  161. 161.
    Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain S, Takaya S, Todo SN, Tzakis A, Van Thiel D, Shannon W, Starzl TE: Neurologic complications of FK506. Transplant Proc 23: 3175–3178, 1991.PubMedGoogle Scholar
  162. 162.
    Scantleburg V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE: New onset diabetes in FK-506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23: 3169–3170, 1991.Google Scholar
  163. 163.
    Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE: FK-506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 23: 3171–3172, 1991.PubMedGoogle Scholar
  164. 164.
    Carroll PB, Boschero AC, Li M-Y, Tzakis AG, Starzl TE, Atwater L: Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation 51: 275–278, 1991.PubMedCrossRefGoogle Scholar
  165. 165.
    Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, Mor E, Sheiner P, Miller CM: Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 57: 1395–1397, 1994.PubMedCrossRefGoogle Scholar
  166. 166.
    Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE: Adverse effects associated with the use of FK506. Transplant Proc 23: 3105–3108, 1991.PubMedGoogle Scholar
  167. 167.
    Vathsala A, Goto S, Yoshimura N, Stepkowski S, Chou T-C, Kahan BD: The immunosuppressive antagonism of low doses of FK506 and cyclosporine. Transplantation 52: 12 1128, 1991.Google Scholar
  168. 168.
    Fukuse T, Hirai T, Yokomise H, Hasegawa S, Hirata T, Muro K, Inui K, Hitomi S, Wada H: Combined therapy with FK506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. J Heart Lung Transplant 12: 941–947, 1993.PubMedGoogle Scholar
  169. 169.
    Kahan BD, Chang JY, Sehgal SN: Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 52: 185–191, 1991.PubMedCrossRefGoogle Scholar
  170. 170.
    Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH: Distinct mechanism of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144: 251–258, 1990.PubMedGoogle Scholar
  171. 171.
    Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S: Synergistic effect of the rapamycin/cyclosporine combination: median effect analysis of in vitro performances by human T lymphocytes in PHA, CD3 and MLR proliferative and cytotoxicity assays. Transplant Proc 23: 1090–1091, 1991.PubMedGoogle Scholar
  172. 172.
    Chang JY, Sengal SN, Bansbach CC: FK506 and rapaymcin: novel pharmacological probes of the immune response. Trends Pharmacol Sci 12: 218–223, 1991.PubMedCrossRefGoogle Scholar
  173. 173.
    Morris RE: Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 6: 39–87, 1992.CrossRefGoogle Scholar
  174. 174.
    Daloze P, Chen H, Luo H, Xu D, Wu J: Rapaymcin’s longterm effect on humoral and cellular immune responses in the rat. Transplant Proc 25: 721–722, 1993.PubMedGoogle Scholar
  175. 175.
    Kimball PM, Kerman RH, Kahan BD: Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 51: 486–490, 1991.PubMedCrossRefGoogle Scholar
  176. 176.
    Morris RE, Wu J, Shorthouse R: A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc 22: 1638–1641, 1990.PubMedGoogle Scholar
  177. 177.
    Collier DSJ, Caine R, Thiru S, Lim S, Pollard SG, Barron P, Dacosta M, White RJ: Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 22: 1674–1675, 1990.PubMedGoogle Scholar
  178. 178.
    Stepkowski SM, Chen H, Daloze P, Kahan BD: Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplant Proc 23: 507–508, 1991.PubMedGoogle Scholar
  179. 179.
    Chen HF, Wu JP, Lu HY, Daloze PM: Reversal of ongoing rejection of allografts by rapamycin. Transplant Proc 23: 2241–2242, 1991.PubMedGoogle Scholar
  180. 180.
    Wang M, Stepkowski SM, Ferraresso M, Kahan BD: Rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation 54: 704–709, 1992.PubMedCrossRefGoogle Scholar
  181. 181.
    Boyle MJ, Kahan BD: Immunosuppressive role of rapamycin in allograft rejection. In: AW Thomson, TE Starzl, eds, Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. Edward Arnold, London, pp 129–140, 1994.Google Scholar
  182. 182.
    Meiser BM, Billingham ME, Morris RE: Effects of cyclosporine, FK506 and rapamycin on graft vessel disease. Lancet 338: 1297–1298, 1991.PubMedCrossRefGoogle Scholar
  183. 183.
    Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME, Morris RE: Effect of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25: 770–771, 1993.PubMedGoogle Scholar
  184. 184.
    Whiting PH, Woo J, Adam BJ, Hasan NU, Davidson RJ, Thomson AW: Toxicity of rapamycin-a comparative and combination study with cyclosporine at immunotherapeutic doses in the rat. Transplantation 52: 203–208, 1991.PubMedCrossRefGoogle Scholar
  185. 185.
    Kahan BD, Tejpal N, Gibbons-Stubbers S, Tu Y, Wang M, Stepkowski S, Chou TC: The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. Transplantation 55: 894–900, 1993.PubMedCrossRefGoogle Scholar
  186. 186.
    Williams JW, Xiao F, Foster PF, Chong A, Sharma S, Bartlett R, Sankarg HN. Immunosuppressive effects of leflunomide in a cardiac allograft model. Transplant Proc 25: 745–746, 1993.PubMedGoogle Scholar
  187. 187.
    Chong AS-F, Finnegan A, Jiang XL, Gebel H, Sankarg HN, Foster P, Williams JW: Leflunomide, a novel immunosupressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 55: 1361–1366, 1993.PubMedCrossRefGoogle Scholar
  188. 188.
    Kuchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR: Prevention of kidney and skin allograft rejection in rats by leflunomide, a new immunosuppressive agent. Transplant Proc 23: 1083–1086, 1991.PubMedGoogle Scholar
  189. 189.
    Schorlemmer HU, Seiler FR, Bartlett RR: Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 25: 763–767, 1993.PubMedGoogle Scholar
  190. 190.
    Reichenspurner H, Hildebrandt A, Human PA, Boehm DH, Rose AG, Odell JA, Reichart B, Schorlemmer HU: 15deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 50: 181–185, 1990.PubMedCrossRefGoogle Scholar
  191. 191.
    Waaga AM, Jlrichs K, Krzymanski M, Treumer J, Hansmann ML, Rommel T, Muller-Ruchholtz W: The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 22: 1613–1614, 1990.PubMedGoogle Scholar
  192. 192.
    Valdivia LA, Monden M, Gotoh M, Nakano Y, Tono T, Mori T: Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejectoion in rats by suppression of antibody formation. Transplantation 50: 132–136, 1990.PubMedCrossRefGoogle Scholar
  193. 193.
    Tepper MA, Petty B, Bursuker I, Pasternak RD, Cleaveland J, Spitalny GL, Schacter B: Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 23: 328–331, 1991.PubMedGoogle Scholar
  194. 194.
    Yuh DD, Morris RE: 15-deoxyspergualin is a more potent and effective immunosuppressant than cyclosporine but does not effectively suppress lymphoproliferation in vivo. Transplant Proc 23: 535–539, 1991.PubMedGoogle Scholar
  195. 195.
    Gannedahl G, Karlsson-Parra A, Totterman TH, Tufveson G: 15-deoxyspergualin inhibits antibody production in mouse to rat heart transplantation. Transplant Proc 25: 778–780, 1993.PubMedGoogle Scholar
  196. 196.
    Schorlemmer HU, Dickneite G, Seiler FR: Treatment of acute rejection epsiodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin. Transplant Proc 22: 1626–1630, 1990.PubMedGoogle Scholar
  197. 197.
    Nemoto K, Hayashi M, Ito J, Saguwara Y, Mae T, Fujil H, ABE F, Takeuchi T: Deoxyspergualin in lethal murine graftversus-host disease. Transplantation 51: 712–715, 1991.PubMedCrossRefGoogle Scholar
  198. 198.
    Yabuuchi H, Nakajima Y, Segawa M, Kanehiro H, Murao Y, Hisanaga M, Yoshimura A, Wada T, Nakagawa K, NakanoH: Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. Transplant Proc 23: 859–861, 1991.PubMedGoogle Scholar
  199. 199.
    Okazaki H, Sato T, Jimbo M, Senga S, Amada N, Oguma S: Prophylatic use of deoxyspergualin in living related renal transplantation. Transplant Proc 23: 1094–1095, 1991.PubMedGoogle Scholar
  200. 200.
    Koyama I, Amemiya H, Taguchi Y, Wanatage T, Nagashima N, Suzuki S, Omoto R: Prophylatic use of deoxyspergualin in a quadruple immunosuppressive protocol in renal transplantation. Transplant Proc 23: 1096–1098, 1991.PubMedGoogle Scholar
  201. 201.
    Okazaki H, Sato T, Amada N: Further study of deoxyspergualin prophylaxis in living related renal transplantation. Transplant Proc 25: 772–773, 1993.PubMedGoogle Scholar
  202. 202.
    Takahashi K, Ota K, Tanabe K, Oba S, Teraoka S, Toma H, Agishi T, Kawaguchi H, Ito K: Effect of a novel immunosuppressive agent, deoxyspergualin, on rejection in kidney transplant recipients. Transplant Proc 22: 1606–1612, 1990.PubMedGoogle Scholar
  203. 203.
    Amemiya H, Dohi K, Otsubo O, Endo T, Nagano S, Ishibashi M, Hirano T, Sato K, Kurita T, Fukao K: Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipients. Transplant Proc 23: 1087–1089, 1991.PubMedGoogle Scholar
  204. 204.
    Amemiya H, Taguchi Y, Fukao K, Isono K, Ornato R, Ota K, Kosaki M, Takagi H, Oka T, Sonoda T, Orita K, Dohi K: Establishment of rejection therapy with deoxyspergualin by multicentral controlled clinical studies in renal recipients. Transplant Proc 25: 730–733, 1993.PubMedGoogle Scholar
  205. 205.
    Borg AJ, Ohlman S: 15-deoxyspergualin treatment of graft rejection in man: effect on mononuclear cells. Transplant Int 5: 219–225, 1992.Google Scholar
  206. 206.
    Ohlman S, Zilg H, Schindel F, Lindholm A: Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transplant Int 7:510, 1994.Google Scholar
  207. 207.
    Groth CG, Ohlman S, Ericzon BG, Barkholt L, Reinholt FP: Deoxyspergualin for liver graft rejection. Lancet 336: 626, 1990.PubMedCrossRefGoogle Scholar
  208. 208.
    Matas AJ, Gores PK, Kelley SL, Bielefield-Skrokov M, Kinaszezuk M, Gruessner RWG, Najarian JS: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant 8: 116–119, 1994.PubMedGoogle Scholar
  209. 209.
    Badger AM, DiMartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N: Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SKF 105685 and related azaspiranes. Int J Immunopharmacol 11: 839–846, 1989.PubMedCrossRefGoogle Scholar
  210. 210.
    Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N: Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SKF 105685. J Autoimmunol 3: 485–500, 1990.CrossRefGoogle Scholar
  211. 211.
    Badger AM, Albrightson-Winslow CR, Kupiec-Weglinski JW: SKF 105685: a novel immunosuppressive compound with efficacy in animal models of autoimmunity and transplantation. Transplant Proc 23: 194–195, 1991.PubMedGoogle Scholar
  212. 212.
    Schmidbauer G, Hancock WW, Badger AM, KupiecWeglinski JW: Induction of nonspecific x-irradition-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SKF 105685, a novel immunomodulatory azaspirane. Transplantation 55: 1236 1243, 1993.Google Scholar
  213. 213.
    Schmidbauer G, Hancock WW, Badger AM, KupiecWeglinski JW: SKF treatment induces suppressor cell activity and modulates cell adhesion properties in rat recipients of cardiac allografts. Transplant Proc 25: 758–760, 1993.PubMedGoogle Scholar
  214. 214.
    Fan P-Y, Albrightson CR, Howell DN, Best C, Badger AM, Coffman TM: The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. J Am Soc Nephrol 3: 1680–1685, 1993.PubMedGoogle Scholar
  215. 215.
    Tax WJM, van de Heijden HMW, Willems HW, Hoitsma AJ, Berden JHM, Capel PJA, Koene RAP: Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc 19: 1905–1907, 1987.PubMedGoogle Scholar
  216. 216.
    Chatenoud L, Ferran C, Legendre C, Kurile R, Kreis H, Bach JF: Immunological follow-up of renal allograft recipients treated with BMA 031 (anti-TCR) monoclonal antibody. Transplant Proc 22: 1787–1788, 1990.PubMedGoogle Scholar
  217. 217.
    Dendorfer U, Hillebrand G, Kasper C, Smely S, Weschka M, Hammer C, Racenberg J, Gurland HJ, Land W: Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantaton: use of high doses of the new monoclonal antibody BMA 031. Transplant Proc 22: 1789–1790, 1990.PubMedGoogle Scholar
  218. 218.
    Pfeffer PF, Ohlman S, Jakobsen A, Fauchald P, Leivestad T, Tyden G, Flatmark A: A Scandinavian two-center study of BMA031 in steroid-resistant rejection of renal grafts. Transplantation 56: 304–307, 1993.PubMedCrossRefGoogle Scholar
  219. 219.
    Schlitt HJ, Kurrle R, Wonigiet K: T cell activation by monoclonal antibody directed to different epitopes on the human T cell receptor/CD3 complex: evidence for two different modes of activation. Eur J Immunol 19: 1649–1655, 1989.PubMedCrossRefGoogle Scholar
  220. 220.
    Kurrle R, Kanzy EJ, Racenberg J, Lang W, Seiler FR: BMA 031-a TCR-specific monoclonal antibody for clinical application. Transplant Proc 21: 1017–1019, 1989.PubMedGoogle Scholar
  221. 221.
    Smely S, Weschka M, Hillebrand G, Dendorfer U, Krombach F, Kurrle R, Land W, Hammer C: Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation. Transplant Proc 22: 1785–1786, 1990.PubMedGoogle Scholar
  222. 222.
    Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS: TI0B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis 14 (Suppl 2): 61–70, 1989.PubMedGoogle Scholar
  223. 223.
    Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53: 80–86, 1992.PubMedCrossRefGoogle Scholar
  224. 224.
    Waid TH, Lucas BA, Thompson JS, Brown S, Moore D, Amlot P, Janossy G: Treatment of acute cellular kidney allograft rejection with T10B9.1A-31 anti-T-cell monoclonal antibody. Transplant Proc 21: 1778–1784, 1989.PubMedGoogle Scholar
  225. 225.
    Kirkman RL, Shapiro ME, Carpenter CB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB: Early experience with anti-Tac in clinical renal transplantation. Transplant Proc 21: 1766–1768, 1989.PubMedGoogle Scholar
  226. 226.
    Cantarovich D, LeMauff B, Hourmant M, Giral M, Denis M, Jacques Y, Soulillou JP: Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant Proc 21: 1769–1771, 1989.PubMedGoogle Scholar
  227. 227.
    Cantarovich D, LeMauff B, Hourmant M, Dantal J, Baatard R, Denis M, Jacques Y, Karam G, Paineau J, Soulillou JP: Prevention of acute rejection episodes with an antiinterleukin 2 receptor monoclonal antibody: results after combined pancreas and kidney transplantation. Transplantation 57: 198–203, 1994.PubMedCrossRefGoogle Scholar
  228. 228.
    Norman DJ, Bennett WM, Cobanoglu A, Hershberger R, Hosenpud JD, Meyer MM, Misiti J, Ott G, Ratkovec R, Shihab F, Vitow C, Barry JM: Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplanta-tion: initial clinical experience. Transplant Proc 25: 802–803, 1993.PubMedGoogle Scholar
  229. 229.
    Morel P, Vincent C, Cordier G, Panaye G, Carosella E, Revillard JP: Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin Immunol Immunopathol 56: 311–322, 1990.PubMedCrossRefGoogle Scholar
  230. 230.
    Reinke P, Volk HD, Miller H, Neuhaus K, Fietze E, Herberger J, Herberger D, Baehr RV, Emmrich F: AntiCD4 therapy of acute rejection in long-term renal allograft recipients. Lancet 338: 702–703, 1991.PubMedCrossRefGoogle Scholar
  231. 231.
    Meiser BM, Reiter C, Ebel M, Uberfuhr P, Wenke K, Reichenspurner H, Rieber E, Riethmuller G, Reichart B: A new chimeric monoclonal CD4 antibody for prevention of rejection after heart transplantation. Transplant Proc 24: 1734, 1992.PubMedGoogle Scholar
  232. 232.
    Marlin SD, Springer TA: Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function associated antigen (LFA1). Cell 51: 813–819, 1987.PubMedCrossRefGoogle Scholar
  233. 233.
    Stauton DE, Dustin MI, Springer TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA1 homologous to ICAM-1. Nature 339: 61–64, 1989.CrossRefGoogle Scholar
  234. 234.
    Dijken PJV, Ghayur T, Mauch P, Down J, Burakoff SJ, Ferrara JLM: Evidence that anti-LFA1 in vivo improves engraftment and survival after allogeneic bone marrow transplantation. Transplantation 49: 882–886, 1990.PubMedCrossRefGoogle Scholar
  235. 235.
    Fischer A, Griscelli C, Blanche S, Deist FL, Veber F, Lopez M, Delaage M, Olive D, Mawas C, Janossy G: Prevention of graft failure by anti-LFA1 monoclonal antibody in HLA matched bone marrow transplantation. Lancet 2: 1058–1061, 1986.PubMedCrossRefGoogle Scholar
  236. 236.
    Maraninchi D, Mawas C, Reiffers J, Gaspard MH, Laurent G, Stoppa A, Hirn M, Delaage M: Anti-LFA1 monoclonal antibody and bone marrow graft rejection in adults. Lancet 2: 579–580, 1988.PubMedCrossRefGoogle Scholar
  237. 237.
    LeMauff B, Hourrmant M, Rougier JP, Hirn M, Dantal J, Baatard R, Cantarovich D, Jacques Y, Soulillou JP: Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 52: 291–296, 1991.CrossRefGoogle Scholar
  238. 238.
    Haug CE, Colvin RB, Delmonico FL, Auchincloss H, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB: A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAB in renal allograft recipients. Transplantation 55: 766–772, 1993.PubMedCrossRefGoogle Scholar
  239. 239.
    Milford EL, Carpenter CB, Kirkman RL, Tilney NL, Mazoujian G, Strom TB, Lazarus JM, Schlossman SF, Guttmann RD, Lowry R, Rocher L, Campbell DA, Salomon DR, Pfaff WW: Anti-T12 monoclonal antibody therapy of acute renal allograft rejection. Transplant Proc 19: 1910, 1987.PubMedGoogle Scholar
  240. 240.
    Levin B, Hoppe RT, Collins G, Miller E, Waer M, Bieber G, Girinsky T, Strober S: Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin, and low-dose prednisone. Lancet 2: 1321–1325, 1985.PubMedCrossRefGoogle Scholar
  241. 241.
    Vanrenterghem Y, Waer M, Roels L, Michielsen P: A controlled trial comparing pretransplant total lymophoid irradiation versus posttransplant cyclosporine in type I diabetic cadaveric kidney graft recipients: short-term results. Transplant Proc 19: 1542–1543, 1987.PubMedGoogle Scholar
  242. 242.
    Myburgh JA, Meyers AM, Botha JR, Thompson PD, Smith JA, Browde S, Lakier R: Wide field low-dose total lymphoid irradiation in clinical kidney transplantation. Transplant Proc 19: 1974–1977, 1987.PubMedGoogle Scholar
  243. 243.
    Strober S, Dhillon M, Schubert M, Holm B, Engleman E, Benike C, Hoppe R, Sibley R, Myburgh JA, Collins G: Acquired immune tolerance to cadaveric renal transplants. N Engl J Med 321: 28–33, 1989.PubMedCrossRefGoogle Scholar
  244. 244.
    Molajoni ER, Bachetoni A, Anti P, Poli L, Caricato M, Pretagostini R, Vetere A, Bertoco P, Alfani D, Cortesini R: Eight-year actuarial graft and patient survival of kidney transplants in highly immunized recipients pretreated with total lymphoid irradiation: a single-center experience. Transplant Proc 25: 776–777, 1993.PubMedGoogle Scholar
  245. 245.
    Monaco AP, Wood ML: Studies of heterologous anti-lymphocyte serum in mice. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 2: 489–496, 1970.PubMedGoogle Scholar
  246. 246.
    Thomas JM, Carver FM, Foil MB, Pryor WH, Larkin EW, Hall WR, Haisch CE, Thomas JM: Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 36: 104–106, 1983.PubMedCrossRefGoogle Scholar
  247. 247.
    Barber WH, Mankin JA, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ, Diethelm AG: Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51: 70–75, 1991.PubMedCrossRefGoogle Scholar
  248. 248.
    Salvatierra O, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Cochrum K, Hanes D, Stoney RJ, Feduska NJ: Deliberate donor-specific blood transfusions prior to living related renal transplantation: a new approach. Ann Surg 192: 543–552, 1980.PubMedCrossRefGoogle Scholar
  249. 249.
    Alexander JW, First MR, Davies CB, Campbell P, Babcock GF: Donor-specific transfusion-induced tolerance in animals and man: a therapeutic strategy. Transplant Sci 3: 72–75, 1993.Google Scholar
  250. 250.
    Rubin RJ, Cosimi AB, Hirsch MS, Herrin JT: Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 31: 143–145, 1981.PubMedCrossRefGoogle Scholar
  251. 251.
    Hanto DW, Jendrisak MD, So SKS, McCullough CS, Rush TM, Michalski SM, Phelam D, Mohanakumar T: Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation: results of a single institution prospective randomized trial. Transplantation 57: 377384, 1994.Google Scholar
  252. 252.
    Cecka JM, Gjertson D, Terasaki PI: Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high risk groups? Transplant Proc 25: 548–549, 1993.PubMedGoogle Scholar
  253. 253.
    Pfaff WW, Patton PR, Howard RJ, Brunson ME, Ramos EL, Fennell RS, Peterson JC, Scornik JC: Immunosuppression without prophylaxtic antilymphocyte preparations. In: P Terasaki, J Cecka, eds, Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles, pp 237–248, 1993.Google Scholar
  254. 254.
    Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG: Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol 5: 123–127, 1976.PubMedGoogle Scholar
  255. 255.
    Diethelm AG, Sterling WA, Hartley MW, Morgan JM: Alternate-day prednisone therapy in recipients of renal allografts. Arch Surg 111: 867–870, 1976.PubMedCrossRefGoogle Scholar
  256. 256.
    Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE: Longterm alternate day steroid therapy in renal transplantation. Transplantation 34: 78–82, 1982.PubMedCrossRefGoogle Scholar
  257. 257.
    Curtis JJ, Galla JH, Woodf d SY, Lucas BA, Luke RG: Effect of alternate-day pre nisone on plasma lipids in renal transplant recipients. Kidney Int 22: 42–47, 1982.PubMedCrossRefGoogle Scholar
  258. 258.
    Hricik DE, Almawi WY, Strom TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation 57: 979–989, 1994.PubMedGoogle Scholar
  259. 259.
    Kupin W, Venkat KK, Oh HK, Dienst S: Complete replacement of methylprednisolone by azathioprine in cyclosporinetreated primary cadaveric renal transplant recipients. Transplantation 45: 53–55, 1988.PubMedCrossRefGoogle Scholar
  260. 260.
    Hricik DE, Whalen CC, Lautman J, Bartucci MR, Moir EJ, Mayes JT, Schulak JA: Withdrawal of steroids after renal transplantation-clinical predictors of outcome. Transplantation 53: 41–45, 1992.PubMedCrossRefGoogle Scholar
  261. 261.
    Hricik DE, O’Toole M, Schulak JA, Herson J: Steroid-free, cyclosporine-based immunosuppression after renal transplantation: a meta-analysis of controlled trials. J Am Soc Nephrol 4: 1300–1305, 1993.PubMedGoogle Scholar
  262. 262.
    Sinclair NRStC: Low-dose steroid therapy in cyclosporinetreated renal transplant recipients with well-functioning grafts. Can Med Assoc J 147: 613–614, 1992.Google Scholar
  263. 263.
    Hariharan S, Schroeder TJ, Weiskittel P, Alexander JW, First MR: Prednisone withdrawal in HLA identical and one haplotype-matched live-related donor and cadaver renal transplant recipients. Kidney Int 44 (Suppl 43): 30–35, 1993.Google Scholar
  264. 264.
    Sheriff MHR, Yayha T, Lee HA: Is azathioprine necessary in renal transplantation? Lancet 1: 118–120, 1978.PubMedCrossRefGoogle Scholar
  265. 265.
    Schmidt P, Kapsa H, Zazgornik J, Pils P, Balcke P: Renal graft acceptance without azathioprine. Lancet 2: 314, 1978.PubMedCrossRefGoogle Scholar
  266. 266.
    Dandavino R, Trunet P, Descamps B, Kreis H: Prolonged withdrawal of azathioprine in kidney transplantation. Transplant Proc 10: 655–657, 1978.PubMedGoogle Scholar
  267. 267.
    Ozaki A, Iwasaki Y, Miyajima T: Withdrawal of azathioprine after renal transplantation. Transplant Proc 12: 513–514, 1980.PubMedGoogle Scholar
  268. 268.
    Haesslein HC, Pierce JC, Lee HM, Hume DM: Leukopenia and azathioprine management of renal homotransplantation. Surgery 71: 598–604, 1972.PubMedGoogle Scholar
  269. 269.
    Woods JE, de Weerd JH, Johnson WJ, Anderson CF: Splenectomy in renal transplantation-influence on azathioprine sensitivity. JAMA 218: 1430–1431, 1972.CrossRefGoogle Scholar
  270. 270.
    Toussaint C, Kinnaert P, Vereerstraeten P, Dupont E, Van Geertruyen J: Azathioprine is necessary in kidney transplantation. Transplantation 27: 145–146, 1979.CrossRefGoogle Scholar
  271. 271.
    Parfrey PS, Hutchinson TA, Lowry RP, Knaack J, Guttmann RD: The role of azathioprine reduction in late renal allograft failure. Transplantation 39: 147–151, 1985.PubMedCrossRefGoogle Scholar
  272. 272.
    Starzl TE, Weil III R, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA: The use of cyclosporin and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 151: 17–26, 1980.PubMedGoogle Scholar
  273. 273.
    Kahan BD, Mickey R, Flechner SM, Lorber MI, Wideman CA, Kerman RH, Terasaki P, Van Buren CT: Risk factors for cadaveric donor allograft survival in cyclosporineprednisone-treated recipients. Transplant Proc 19: 1835–1838, 1987.PubMedGoogle Scholar
  274. 274.
    MacDonald AS, Daloze P, Dandavino R, Jindal S, Bear L, Dossetor JB, Klassen J, Stiller CR, Lockwood B, Reeve CE, and the Canadian Transplant Group: A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Transplant Proc 19: 1865–1872, 1987.Google Scholar
  275. 275.
    European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: one-year followup of a multicentre trial. Lancet 2: 986–989, 1983.CrossRefGoogle Scholar
  276. 276.
    Merion RM, White DJG, Thiru S, Evans DB, Calne RY: Cyclosporine: five years’ experience in cadaver renal transplantation. N Engl J Med 310: 148–154, 1984.PubMedCrossRefGoogle Scholar
  277. 277.
    Simmons RL, Canafax DM, Strand M, Ascher NL, Payne WD, Sutherland DER, Najarian JS: Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine and prednisone. Transplant Proc 17 (Suppl 1): 266–275, 1985.PubMedGoogle Scholar
  278. 278.
    Fries D, Hiesse C, Charpentier B, Rieu P, Neyrat N, Cantarovich M, Ouziala, Bellamy J, Benoit G: Triple combination of low-dose cyclosporine, azathioprine and steroids in first cadaver donor renal allografts. Transplant Proc 19: 1911 1914, 1987.Google Scholar
  279. 279.
    Henry ML, Sommer BG, Ferguson RM: Triple drug therapy: an alternative regimen in renal transplantation. Transplant Proc 19: 1920–1921, 1987.PubMedGoogle Scholar
  280. 280.
    Terasaki PI, Cecka JM, Lim E, Takemoto S, Cho Y, Gjertson D, Ogura K, Koyama H, Mitsuishi Y, Yuge J, Cohn M: Overview. In: P Terasaki, ed, Clinical Transplants 1991. UCLA Tissue Typing Laboratory, Los Angeles, pp 409–430, 1992.Google Scholar
  281. 281.
    Ihorogood J, van Houwelingen JC, van Rood JJ, Zantvoort FA, Scheuder GMT, Persijn GG: Factors contributing to longterm kidney graft survival in Eurotransplant. Transplantation 54: 152–158, 1992.CrossRefGoogle Scholar
  282. 282.
    Opelz G: Collaborative Transplant Study: 10-year report. Transplant Proc 24: 2342–2355, 1992.PubMedGoogle Scholar
  283. 283.
    European multicenter trial of cyclosporine in renal transplantation: 10-year follow-up. Transplant Proc 25:527–529, 1993.Google Scholar
  284. 284.
    Opelz G: Superior long-term kidney graft survival in patients on maintenance immunosuppression with cyclosporine and azathioprine. Transplant Proc 25: 1289–1290, 1993.PubMedGoogle Scholar
  285. 285.
    Myers BD, Newton L, Oyer P: The case against the indefinite use of cyclosporine. Transplant Proc 23: 41–42, 1991.PubMedGoogle Scholar
  286. 286.
    Hoitsma AJ, Van Lier HJJ, Wetzels JFM, Berden JHM, Koene RAP: Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1: 584–586, 1987.PubMedCrossRefGoogle Scholar
  287. 287.
    Morris PJ, Allen RD, Thompson JF, Chapman JR, Ting A, Dunnill MS, Wood RFM: Cyclosporin conversion versus conventional immunosuppression: long-term followup and histological evaluation. Lancet 1: 586–591, 1987.PubMedCrossRefGoogle Scholar
  288. 288.
    Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation: a meta-analysis. JAMA 269: 395–400, 1993.PubMedCrossRefGoogle Scholar
  289. 289.
    Cecka JM, Terasaki PI: Early rejection episodes. In: P Terasaki, ed, Clinical Transplants 1989. UCLA Tissue Typing Laboratory, Los Angeles, pp 425–434, 1990.Google Scholar
  290. 290.
    Sumrani N, Delaney V, Daskalakis P, Hong JH, Cacciarelli TV, Sommer BG: The detrimental effect of early rejection on long-term renal allograft outcome. Transplant Proc 24: 1750 1752, 1992.Google Scholar
  291. 291.
    Koyama H, Cecka JM: Rejection episodes. In: PI Terasaki, JM Cecka, eds, Clinical Transplants 1992. UCLA Tissue Typing Laboratory, Los Angeles, pp 391–403, 1993.Google Scholar
  292. 292.
    Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS: Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55: 993–995, 1993.PubMedCrossRefGoogle Scholar
  293. 293.
    Tesi RJ, Henry ML, Eldhammas EA, Ferguson RM: Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 7: 345–352, 1993.Google Scholar
  294. 294.
    Stiller CR, Opelz G: Should cyclosporine be continued indefinitely? Transplant Proc 23: 36–40, 1991.PubMedGoogle Scholar
  295. 295.
    Sanders CE, Curtis JJ, Julian BA, Gaston RS, Jones PA, Laskow DA, Deierhoi MH, Barber WH, Phil D, Diethelm AG: Tapering or discontinuing cyclosporine for financial reasons-A single-center experience. Am J Kidney Dis 21: 9–15, 1993.PubMedGoogle Scholar
  296. 296.
    Thiel G, Mihatsch M, Landmann J, Hermle M, Brunner FP, Harder F: Is cyclosporin-A induced nephrotoxicity in recipients of renal allograft progressive? Transplant Proc 17 (Suppl 1): 169–178, 1985.PubMedGoogle Scholar
  297. 297.
    Tilney NL, Milford EL, Carpenter CB, Lazarus JM, Strom TB, Kirkman RL: Long-term results of cyclosporine treatment in renal transplantation. Transplant Proc 18: 179–185, 1986.PubMedGoogle Scholar
  298. 298.
    Snider J, Francis DMA, Kincaid-Smith P, Walker RG: Longterm graft survival and renal function in cyclosporin-treated renal allograft recipients: lack of evidence of nephrotoxicity. Clin Transplant 7: 25–27, 1993.Google Scholar
  299. 299.
    Lewis R, Podbielski J, Sprayberry S, Munsell M, Katz S, Rubin M, Kimball P, Van Buren CT, Kerman R, Kahan B: Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A. Transplantation 55: 1014–1017, 1993.PubMedCrossRefGoogle Scholar
  300. 300.
    Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752–757, 1993.PubMedCrossRefGoogle Scholar
  301. 301.
    Hong CD, Kapoor BS, First MR, Pollak VE, Alexander JW: Fractional excretion of sodium after renal transplantation. Kidney Int 16: 167–178, 1979.PubMedCrossRefGoogle Scholar
  302. 302.
    Sethi K, First MR, Pesce AJ, Fidler JP, Pollak VE: Proteinuria following renal transplantation. Nephron 18:4959, 1977.Google Scholar
  303. 303.
    Woloszczuk W, Troppmair J, Leiter E: Relationshop of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation 41: 716719, 1986.Google Scholar
  304. 304.
    Maury CPJ, Teppo AM: Serum immunoreactive interleukin 1 in renal transplant recipients. Transplantation 45: 143–147, 1988.PubMedCrossRefGoogle Scholar
  305. 305.
    McKenna RM, Rush DN, Bakkestad-Legare P, Jeffrey JR: Interleukin 2, interferon, and lymphotoxin in renal transplant recipients. Transplantation 45: 76–81, 1988.PubMedCrossRefGoogle Scholar
  306. 306.
    van Oers MHJ, van der Heyden AA, Aaren LA: Interleukin 6 in serum and urine of renal transplant recipients. Clin Exp Immunol 71: 314–319, 1988.PubMedGoogle Scholar
  307. 307.
    Colvin RB, Preffer FI, Fuller TC, Brown MC, Ip SH, Kung PC, Cosimi AB: A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 48: 800–805, 1989.PubMedCrossRefGoogle Scholar
  308. 308.
    McLaughlin PJ, Aikawa A, Davies HM: Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 51: 1225 1229, 1991.Google Scholar
  309. 309.
    Schroeder TJ, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First MR, Muth KL: A multicenter study to evaluate a novel assay for quantitation of a soluble interleukin 2 receptor in renal transplant recipients. Transplantation 53: 34–40, 1992.PubMedCrossRefGoogle Scholar
  310. 310.
    Maury CPJ, Teppo AM, Eklund B, Ahonen J: Serum amyloid A protein: a sensitive indicator of renal allograft rejection in humans. Transplantation 36: 501–504, 1983.PubMedCrossRefGoogle Scholar
  311. 311.
    Edwards LC, Helderman JH, Hamm LL, Ludwin D, Gailiunas P, Hull AR: Noninvasive monitoring of renalGoogle Scholar
  312. 312.
    Cohen DJ, Benvenisty AI, Meyer E, Hardy MA: Serum C-reactive protein concentrations in cyclosporine-treated renal allograft recipients. Transplantation 45: 919–922, 1988.PubMedCrossRefGoogle Scholar
  313. 313.
    Schumann GB, Burleson RL: Importance of urine cytology in renal transplantation. Transplantation 23: 186–188, 1977.PubMedCrossRefGoogle Scholar
  314. 314.
    Fidler JP, Dajani F, First MR, Munda R, Alexander JW: Value of urine cytology in renal transplantation. Transplantation 26: 133–135, 1978.PubMedGoogle Scholar
  315. 315.
    Dooper IMM, Bogman MJT, Hoitsma AJ, Maas CN, Vooijs PG, Koene RAP: Immunocytology of urinary sediments as a method of differentiating acute rejection from other causes of declining renal graft function. Transplantation 52: 266–271, 1991.PubMedCrossRefGoogle Scholar
  316. 316.
    von Willebrand E: Fine-needle aspiration cytology of human renal allografts. Clin Immunol Immunopathol 17: 309–322, 1980.CrossRefGoogle Scholar
  317. 317.
    Hayry P, von Willebrand E: Monitoring of human renal allograft rejection with fine-needle aspiration cytology. Scand J Immunol 13: 87–97, 1981.PubMedCrossRefGoogle Scholar
  318. 318.
    Belitsky P, Campbell J, Gupta R: Serial biopsy controlled evaluation of fine needle aspiration in renal allograft rejection. Lab Invest 53: 580–585, 1985.PubMedGoogle Scholar
  319. 319.
    Sheth S: Evaluation of acute renal transplant rejection with duplex sonography. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 459–470, 1992.Google Scholar
  320. 320.
    Rigsby CM, Taylor KW, Weltin GG, Garnes PB, Bia M, Princethol RA, Kashgarian M, Flye WM: Renal allografts in acute rejection: evaluation using duplex sonography. Radiology 158: 375–378, 1986.PubMedGoogle Scholar
  321. 321.
    Rifkin MD, Needleman L, Pasto ME, Kurtz AB, Foy PM, McGlynn E, Canino C, Baltarowich OH, Pennell RB, Goldberg BB: Evaluation of renal transplant rejection by Doppler examination. Value of the resistive index. Am J Radiol 148: 759–762, 1987.Google Scholar
  322. 322.
    Camargo EE, Sostre S: Radionuclides in the evaluation of kidney transplant rejection. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 471–485, 1992.Google Scholar
  323. 323.
    Dubovsky EV, Russel CD: Radionuclide evaluation of renal transplants. Semin Nucl Med 18: 181–198, 1988.PubMedCrossRefGoogle Scholar
  324. 324.
    Tempany CMC, Yang A: Magnetic resonance imaging and magnetic resonance spectroscopy. In: JF Burdick, LC Racusen, K Solez, GM Williams, eds, Kidney Transplant Rejection: Diagnosis and Treatment. Marcel Dekker, New York, pp 487–502, 1992.Google Scholar
  325. 325.
    Geisinger MA, Risius B, Jordan ML, Zelch M, Novick AC, George CR: Magnetic resonance imaging of renal transplants. Am J Radiol 143: 1229–1234, 1984.Google Scholar
  326. 326.
    Mahoney MC, Racadio JM, Merhar GL, First MR: Safety and efficacy of kidney transplant biopsy: Tru-cut needle vs sonographically guided biopty gun. Am J Roentgen 160: 325326, 1993.Google Scholar
  327. 327.
    Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, Hayry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozumi K, Racusen LC, Ramos EL, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, von Willebrand E, Yamaguchi Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classifications of kidney transplant pathology. Kidney Int 44: 411–422, 1993.PubMedCrossRefGoogle Scholar
  328. 328.
    Rush D, Jeffrey J, Gough J: Protocol biopsies in stable renal transplant patients under triple immunosuppression: results at 6 months. Transplant Proc 26: 25–76, 1994.Google Scholar
  329. 329.
    Goodwin WE, Kaufman JJ, Mims MM, Turner RD, Glassock R, Goldman R, Maxwell MM: Human renal transplantation: clinical experience with six cases of renal homotransplantion. J Urol 89: 13–24, 1963.PubMedGoogle Scholar
  330. 330.
    Kauffman HM, Stromstad SA, Sampson D, Stawicki AT: Randomized steroid therapy of human kidney transplant rejection. Transplant Proc 11: 36–38, 1979.PubMedGoogle Scholar
  331. 331.
    Park GD, Bartucci M, Smith MC: High-versus low-dose methylprednisolone for acute rejection episodes in renal transplantation. Nephron 36: 80–83, 1984.PubMedCrossRefGoogle Scholar
  332. 332.
    Mussche MM, Ringoir SMG, Lameire NH: High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 16: 287–291, 1976.PubMedCrossRefGoogle Scholar
  333. 333.
    Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ: Oral versus intravenous high-dose steroid treatment of renal allograft rejection. Lancet 1: 117–118, 1978.PubMedCrossRefGoogle Scholar
  334. 334.
    Orta-Sibu N, Chantler C, Bewick M, Haycock G: Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J 285: 258–260, 1982.CrossRefGoogle Scholar
  335. 335.
    Shield CF, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J, Russel PS: Use of antilymphocyte globulin for reversal of acute rejection. Transplantation 28: 461–464, 1979.PubMedGoogle Scholar
  336. 336.
    Nowygrod R, Appel G, Hardy MA: Use of ATG for reversal of acute allograft rejection. Transplant Proc 13: 469–472, 1981.PubMedGoogle Scholar
  337. 337.
    Hoitsma AJ, Reekers P, Kreftenberg JG, van Lier HJJ, Capel PJA, Koene RAP: Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation 33: 12–16, 1982.PubMedCrossRefGoogle Scholar
  338. 338.
    Broyer M, Niaudet P, Bijaoui, Gagnadoux MF: Treatment of acute rejection crisis by antilymphocyte globulins: a randomized prospective study in pediatric kidney transplant recipients. Transplant Proc 19: 1886–1888, 1987.PubMedGoogle Scholar
  339. 339.
    Hardy MA, Nowygrod R, Erlberg A, Appel G: Use of ATG in treatment of steroid-resistent rejection. Transplantation 29: 162–164, 1980.PubMedCrossRefGoogle Scholar
  340. 340.
    Light JA, Alijani MR, Biggers JA, Oddenino K, Reinmuth B: Antilymphocyte globulin (ALG) reverses irreversible allograft rejection. Transplant Proc 13: 475–481, 1981.PubMedGoogle Scholar
  341. 341.
    Griffin PJA, Williams GT, Salaman JR: Antilymphocyte globulin for the treatment of steroid non-responsive acute renal allograft rejection. Clin Nephrol 21: 115–117, 1984.PubMedGoogle Scholar
  342. 342.
    Matas AJ, Tellis VA, Quinn T, Glichlick D, Soberman R, Weiss R, Karwa G, Veith FJ: ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation 41: 579–583, 1986.PubMedCrossRefGoogle Scholar
  343. 343.
    Veremis SA, Maddux MS, Pollak R, Kline SS, Mozes MF: Alternative antirejection treatment with steroids or antilymphoblast globulin in renal transplant patients receiving cyclosporine. Transplant Proc 19: 1893–1895, 1987.PubMedGoogle Scholar
  344. 344.
    Deierhoi MH, Barber WH, Curtis JJ, Julian BA, Luke RB, Hudson S, Barger BO, Diethelm AG: Treatment of acute rejection by monoclonals. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 11: 86–89, 1988.PubMedGoogle Scholar
  345. 345.
    Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM: OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 55: 1023–1029, 1993.PubMedCrossRefGoogle Scholar
  346. 346.
    Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell PS: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–539, 1981.PubMedCrossRefGoogle Scholar
  347. 347.
    Alamartine E, Bellakoul R, Berthoux F: Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Transplant Proc 26: 273–274, 1994.PubMedGoogle Scholar
  348. 348.
    Anderson P, Schroeder TJ, Hariharan S, First MR: Incidence of post-transplant lymphoproliferative disease in OKT3 treated renal transplant recipients. Clin Transplant 7: 582–585, 1993.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • M. Roy First
    • 1
  1. 1.Division of Nephrology and HypertensionUniversity of Cincinnati Medical CenterCincinnatiUSA

Personalised recommendations